Replies to post #148115 on Biotech Values

[iwfal]

(Had Teva lost that case [Copaxone patent case], which could still eventually happen on appeal, Teva would surely have responded by cutting development programs broadly and deeply.)

The probability of this seems so low as not even worth mentioning given that Momenta lost on multiple fronts. (I have done substantially les tracking of the Copaxone suits compared to the Amphastar suit, but I have yet to see any unifying theme to the Copaxone loss for Momenta.)